Cambium Bio Limited

CHIA:CMB Stock Report

Market Cap: AU$4.7m

Cambium Bio Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Karolis Rosickas

Chief executive officer

AU$739.7k

Total compensation

CEO salary percentage33.8%
CEO tenureno data
CEO ownership0.3%
Management average tenureno data
Board average tenureless than a year

Recent management updates

Recent updates

CEO

Karolis Rosickas

no data

Tenure

AU$739,735

Compensation

Mr. Karolis Rosickas, M.S & M.B.A is Chief Executive Officer of Cambium Bio Limited. He is an experienced executive and healthcare entrepreneur with business experience in healthcare, technology and financ...

Board Members

NamePositionTenureCompensationOwnership
Edmund Waller
Chief Scientific Officer & Executive Directorno dataAU$147.53k1.92%
A$ 89.3k
Terence Walts
Executive Directorno dataAU$448.99k2.23%
A$ 103.7k
Barry Sechos
Non-Executive Chairman12.9yrsAU$85.00k0.65%
A$ 30.0k
Barbara Fant
Member of Advisory Boardno datano datano data
Yu-Hung Tseng
Non-Executive Directorless than a yearno data2%
A$ 93.0k
Doyle Stulting
Member of Advisory Boardno datano datano data
Gary Stevens
Member of Advisory Boardno datano datano data
Chi-Tai Chang
Directorless than a yearno datano data
Louis Tong
Member of Advisory Boardless than a yearno datano data
Chandra Bala
Directorless than a yearno datano data

0.2yrs

Average Tenure

Experienced Board: CMB's board of directors are not considered experienced ( 0.2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 05:20
End of Day Share Price 2024/12/13 00:00
EarningsN/A
Annual EarningsN/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cambium Bio Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution